TrialInternational journal of clinical oncology2022

Pembrolizumab in advanced NSCLC patients with poor performance status and high PD-L1 expression: OLCSG 1801.

Shinobu Hosokawa et al.PubMed ↗Publisher ↗

No numbers read from the abstract.